54
Participants
Start Date
May 31, 2005
Primary Completion Date
March 31, 2007
Study Completion Date
March 31, 2007
Epratuzumab
360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
Placebo
Intravenous
Birmingham
Tucson
Los Angeles
Upland
Colorado Springs
Denver
Farmington
Washington D.C.
Aventura
Chicago
Baltimore
New York
Plainview
Rochester
Syracuse
The Bronx
Durham
Winston-Salem
Gallipolis
Tulsa
Philadelphia
Charleston
Dallas
Arlington
Edmonds
Brussels
Liège
Rio de Janeiro
Goiânia
Rio de Janeiro
São Paulo
Sorocaba
Winnipeg
St. John's
Hradec Králové
Olomouc
Prague
Paris
Toulouse
Erlangen
Heidelberg
Mannheim
München
Ancona
Brescia
Amsterdam
Groningen
Leiden
Barcelona
Madrid
San Cristóbal de La Laguna
Santander
Seville
Leeds
Birmingham
London
Manchester
Newcastle upon Tyne
Sheffield
United Kingdom
Lead Sponsor
UCB Pharma
INDUSTRY